Promising combo for brain metastases hits early snag: trial ends after just one patient
NCT ID NCT05553522
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial aimed to see if combining three drugs (tucatinib, trastuzumab, and capecitabine) with precise radiation (SRS) is safe for people with HER2-positive breast cancer that has spread to the brain. Only one person enrolled before the study was terminated, so we have very little information. The main goal was to find the safest dose and watch for side effects like low blood counts or radiation-related issues.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tucatinib, trastuzumab, capecitabine, and stereotactic radiosurgery
What this could lead to
If it works, this could point toward a treatment that controls brain metastases from HER2-positive breast cancer using a combination of targeted drugs and precise radiation.
What could go wrong
This was a very early Phase 1 trial with only 1 participant and was terminated, so we have almost no data on safety or effectiveness. The combination may cause serious side effects like low blood counts or lung inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Miami Cancer Institute at Baptist Health, Inc.
Miami, Florida, 33176, United States